(VIANEWS) – The NASDAQ opens in less than six hours and Xenetic Biosciences‘s pre-market value is already 15.21% down.
Xenetic Biosciences’s last close was $0.48, 61.28% under its 52-week high of $1.25.
The last session, NASDAQ finished with Xenetic Biosciences (XBIO) sliding 3.2% to $0.48. NASDAQ rose 1.97% to $11,689.01, after two successive sessions in a row of gains, on what was an all-around up trend exchanging session.
About Xenetic Biosciences
Xenetic Biosciences, Inc., a biopharmaceutical company, focuses on advancing XCART, a personalized chimeric antigen receptor T cell (CAR T) platform technology engineered to target patient-specific tumor neoantigens. The company engages in the discovery, research, and development of biologic drugs and oncology therapeutics. It advances cell-based therapeutics targeting the B-cell receptor on the surface of an individual patient's malignant tumor cells for the treatment of B-cell lymphomas. It is also leveraging PolyXen, its proprietary drug delivery platform, by partnering with biotechnology and pharmaceutical companies. It has collaboration agreements with Takeda Pharmaceutical Co. Ltd., Serum Institute of India Limited, PJSC Pharmsynthez, and SynBio LLC. Xenetic Biosciences, Inc. is headquartered in Framingham, Massachusetts.
Earnings Per Share
As for profitability, Xenetic Biosciences has a trailing twelve months EPS of $-1.704.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -39.85%.
Moving Average
Xenetic Biosciences’s worth is above its 50-day moving average of $0.47 and way below its 200-day moving average of $0.62.
More news about Xenetic Biosciences (XBIO).
